Back to top

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying ...

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in Chi

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Instil Bio, Inc. (TIL)